Gilead Sciences Inks $247M Deal For HIV Antitrust Claims
Gilead has agreed to pay direct purchasers of its HIV medications $246.8 million, ending claims the pharmaceutical company cut a deal with Teva to delay generic versions after reaching an initial...To view the full article, register now.
Already a subscriber? Click here to view full article